利索-全球专利检索

  1. 登录
  2. 注册
发明授权
US08901278B2 Pharmaceutical antibody compositions with resistance to soluble CEA 有权
具有抗CEA抗性的药物抗体组合物

Pharmaceutical antibody compositions with resistance to soluble CEA
摘要：
The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” (SEQ ID NO: 29) and a CDR-H2 having the amino acid sequence “FIRNKANGGTTEYAASVKG” (SEQ ID NO: 28) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27) or (ii) a CDR-H1 having the amino acid sequence “TYAMH” (SEQ ID NO: 31) and a CDR-H2 having the amino acid sequence “LISNDGSNKYYADSVKG” (SEQ ID NO: 30) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27). Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the IgG1 antibody molecules bearing specificities for the human CEA antigen are disclosed.
摘要（中）：

本发明涉及用于治疗人类上皮肿瘤的药物组合物，所述药物组合物包含与人CEA特异性结合的IgG1抗体，其中所述IgG1抗体的可变区至少包含（i）具有 氨基酸序列“SYWMH”（SEQ ID NO：29）和具有氨基酸序列“FIRNKANGGTTEYAASVKG”（SEQ ID NO：28）的CDR-H2和具有氨基酸序列“DRGLRFYFDY”（SEQ ID NO： （SEQ ID NO：31）的CDR-H1和具有氨基酸序列“LISNDGSNKYYADSVKG”（SEQ ID NO：30）的CDR-H2和CDR -H3，具有氨基酸序列“DRGLRFYFDY”（SEQ ID NO：27）。 此外，公开了用于生产所述药物组合物的方法以及具有人CEA抗原特异性的IgG1抗体分子的医疗/药物用途。

公开/授权文献
信息查询
Espacenet
0/0